Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update - Wikidata - awgldk - TriplyDB

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update

http://www.wikidata.org/entity/Q34421634

about

Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives Soy Isoflavones and Breast Cancer Cell Lines: Molecular Mechanisms and Future Perspectives Breast cancer and sexual function Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer Current medical treatment of estrogen receptor-positive breast cancer The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds Identifying and targeting tumor-initiating cells in the treatment of breast cancer Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline Adjuvant treatment for older women with invasive breast cancer Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review Critical appraisal of paroxetine for the treatment of vasomotor symptoms Spiro[pyrrolidine-3, 3´-oxindole] as potent anti-breast cancer compounds: Their design, synthesis, biological evaluation and cellular target identification Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation.Adjuvant therapy use among Appalachian breast cancer survivors 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).Phenotype anchoring in zebrafish reveals a potential role for matrix metalloproteinases (MMPs) in tamoxifen's effects on skin epithelium.Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study Data integration to prioritize drugs using genomics and curated data.A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy "Winging It": How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment.Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population The best of both worlds - managing the cancer, saving the bone.Effects of age on the detection and management of breast cancer.Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations.How can we best respect patient autonomy in breast cancer treatment decisions?Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer.Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.Hypomethylation of DNA-binding inhibitor 4 serves as a potential biomarker in distinguishing acquired tamoxifen-refractory breast cancer Cost-utility analyses of drug therapies in breast cancer: a systematic review.

P2860

Q24273274-56817042-17BF-4612-852E-20B175451361 Q26768119-C6A9F0A3-D097-40F8-A17D-F40CABD9EA13 Q26772042-4302C87A-7676-438B-A819-BF92C8A449CF Q26773714-139AA199-A17D-4B08-BB82-5132CCD73B11 Q26782494-7BA9168A-5367-4C84-9B6F-7B5D5049FB6E Q26795751-023239F3-2447-4DF8-8583-1F74046CABAA Q26799120-D4F63362-F171-416D-8B59-A08F475C5B19 Q26851827-C56A2497-5410-4680-B71C-B1A7F5102EA3 Q27002430-9C4603B4-22E7-4721-A07A-6CD8FBC96756 Q28066744-3F357EBC-B2D1-4391-B572-F3F0D2C5EF2F Q28074177-ED7C9517-3BF5-459D-B4FF-04704E28A825 Q28081319-2F3008E1-665D-4D1B-A5B8-CA7F0DAA5DAF Q28082674-D4003575-CC7B-4589-9308-D50D7889CC49 Q28084597-93D62399-FAA6-487B-BA13-731A59B0D62D Q28828506-276DAC15-890E-4455-9E10-87FA9F9823C4 Q30239964-E26DC8E9-87EB-453E-8B54-F4338AD5598C Q30279083-60AB6281-0B36-410D-AEBF-1471F53FEC2E Q30315970-7B5F14D5-8A71-4721-A0AE-ED801DB39196 Q30316383-5FF3AAFF-0D00-44E4-84EF-AC6452B976CD Q30727473-AC4F790F-70F7-46E4-BB89-7B305921B749 Q30758966-403B96FD-FC0B-4F53-AB4B-B43FF4624AA8 Q31102946-2F283EED-FCA4-49EF-9ADA-AEFA25163BA7 Q33605919-17FA9BB3-549A-490B-AAFA-F0447DE1DA1C Q33756757-F817F3EB-4DE4-4C89-B1A1-29B340C22AF9 Q33919320-80789C9C-419D-4E0A-9CAD-8CCFC60DEC81 Q33920055-70AE17FA-B236-4684-AC8F-DBD4B4956AB7 Q34477879-D00313A3-B67A-4AAF-8E11-079662D4216F Q34490225-F3F9BFA6-358B-42CE-B4B6-C430DD213AAC Q35060868-4BE2E277-6DCD-476A-B05D-F652E7B238D9 Q35127923-6CD962D3-BDA8-495C-90E6-35F3C39E2F00 Q35164117-1995F91E-9FD6-4B97-9360-07AB826465B8 Q35207952-8B072B5D-B7CC-4DB5-AE77-D38166088CDF Q35445037-E8F77C58-3AFC-4E41-9EE9-E9BDA1B6209A Q35490056-78D321F7-8468-4832-933C-EDC2DB539231 Q35845258-39196E8D-9B92-42FA-8939-1CCDC4CE0B4F Q35963517-487DE5C0-9579-4D60-B9C6-D54118BFFA38 Q36064866-884CC4A2-5582-485C-9349-D91AC8D2992B Q36070063-35BEA45A-95BA-4856-B9DD-90DBFA0D44DB Q36095385-8137D2C3-6FD0-4806-83F3-F80FE1B6528B Q36116276-7A96DF77-9A25-4C7E-849E-61B6E6A8FD15

P2860

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update

http://www.wikidata.org/entity/Q34421634

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Adjuvant endocrine therapy for ...... ctice guideline focused update

@ast

Adjuvant endocrine therapy for ...... ctice guideline focused update

@en

Adjuvant endocrine therapy for ...... ctice guideline focused update

@nl

type

label

Adjuvant endocrine therapy for ...... ctice guideline focused update

@ast

Adjuvant endocrine therapy for ...... ctice guideline focused update

@en

Adjuvant endocrine therapy for ...... ctice guideline focused update

@nl

prefLabel

Adjuvant endocrine therapy for ...... ctice guideline focused update

@ast

Adjuvant endocrine therapy for ...... ctice guideline focused update

@en

Adjuvant endocrine therapy for ...... ctice guideline focused update

@nl

P1433

Q34421634-4FC0DB27-5A51-49B0-8EC7-C045589CAF5C

P1476

Q34421634-39016797-82E7-4474-81E8-8DAFADA51522

P2093

Q34421634-140A21A1-BD61-4BB5-9EE0-90F25DA78420

Q34421634-2817E6CF-8086-4637-B553-BB48887300A6

Q34421634-336E8D70-76A9-46D6-8B44-10A84AD9B50F

Q34421634-3D46BCF7-FFDF-4B0D-8494-83D4BC83AF32

Q34421634-4D7F03B4-CA98-48BB-8633-CC1C192612FA

Q34421634-619FF939-E732-4133-8072-FF2984883A1D

Q34421634-699C8DD3-F8EC-4A3F-85A2-E61BA3AD7F8A

Q34421634-832AD3B5-2A39-4B3F-9B95-C8738AC3933E

Q34421634-DBC02A1E-A46A-4A06-83A1-93C88C3614D3

Q34421634-E4A89E56-CDE4-48A0-B799-4CEC98D62725

P2860

Q34421634-00C70A81-8781-4144-9E7B-B10248F8DD65

Q34421634-09DD74A1-AD7B-474E-AF19-4BB78AD2F086

Q34421634-0C589E40-26A1-44F7-B0F9-D1B6E4F70FA6

Q34421634-1CC921ED-6CE6-4698-9960-BDADB442F50D

Q34421634-222C4C49-4D68-494A-B077-BF9E50BA134E

Q34421634-324F641A-AC91-45EB-B854-AF4703E9DA59

Q34421634-36B6256A-9CD0-4B43-A31D-5C0C74EACFE3

Q34421634-49C1D213-A9BF-4842-B876-80B535A9844B

Q34421634-54A2193C-406F-4031-87FA-AD643E90DDFB

Q34421634-56055A15-ADCC-4A96-8E60-035378DBC8B0

P304

Q34421634-70FDA644-325D-43A0-81BA-506E78DAFF49

P31

Q34421634-08F3A9B7-8A25-4228-93B7-E2262BBAAB7B

P356

Q34421634-E0146D6C-3262-4D55-A1AC-46DDE9C76972

P407

Q34421634-80891435-530D-494E-9516-0DFDE7EB9FEF

P433

Q34421634-81225135-165F-4932-A4F9-B61EFB7DC14D

P478

Q34421634-94F7C13A-2691-4BAD-8A78-4CA2F9EC42F7

P50

Q34421634-8FE5A21F-8A03-488F-A03B-18308F469D7E

Q34421634-D0B269A4-82C0-4041-98EC-A5C48BAF11FA

P577

Q34421634-11F98106-AA3F-4191-AFBA-FF68E50984E6

P698

Q34421634-F9D733F6-B7D8-4B77-9C3A-BD5D10562F07

P932

Q34421634-1DA1B801-A880-4A35-94B6-09BEA569C4D6

P356

JCO.2013.54.2258

P1433

Journal of Clinical Oncology

P1476

Adjuvant endocrine therapy for ...... ctice guideline focused update

@en

P2093

Alexander J Solky

http://www.w3.org/2001/XMLSchema#string

Clifford A Hudis

http://www.w3.org/2001/XMLSchema#string

Diana Rowden

http://www.w3.org/2001/XMLSchema#string

Eric P Winer

http://www.w3.org/2001/XMLSchema#string

Harold J Burstein

http://www.w3.org/2001/XMLSchema#string

Holly Anderson

http://www.w3.org/2001/XMLSchema#string

Jennifer J Griggs

http://www.w3.org/2001/XMLSchema#string

Karen E Gelmon

http://www.w3.org/2001/XMLSchema#string

Nancy E Davidson

http://www.w3.org/2001/XMLSchema#string

Sarah Temin

http://www.w3.org/2001/XMLSchema#string

P2860

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Socioeconomic factors associated with adjuvant hormone therapy use in older breast cancer survivors

Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability.

Patient-centered care for older adults with multiple chronic conditions: a stepwise approach from the American Geriatrics Society: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Letrozole in the extended adjuvant setting: MA.17

Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.

P304

2255-2269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.54.2258

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Sharon H. Giordano

P577

2014-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24868023

http://www.w3.org/2001/XMLSchema#string

P932

4876310

http://www.w3.org/2001/XMLSchema#string